Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Thrombosis resisting composition

A composition and anti-thrombotic technology, applied in the directions of drug combination, blood diseases, medical raw materials derived from reptiles, etc., can solve the problems of missed optimal treatment time, low effective rate, adverse consequences, etc., and achieve the effect of inhibiting platelet aggregation, Improve the efficiency and prevent the effect of thrombus regeneration

Inactive Publication Date: 2003-08-20
田兆军
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] thromboxane A 2 (TXA 2 ) synthetase inhibitors, which have been used to treat acute cerebral thrombosis (such as Ozagrel Sodium, Ozagrel Sodium), but because they can only prevent thrombus formation, they have no direct effect on the formation of thrombus, so the onset is slow (generally Effective after 2 days of medication), the effective rate is low (data show that its effective rate is only 49.2%); within 8 hours) to dissolve the thrombus and reperfuse the blood flow
Thus, only thromboxane A 2 (TXA 2 ) synthetase inhibitors in the treatment of acute cerebral thrombosis may miss the best treatment time, resulting in adverse consequences

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Example 1 Zagrel sodium 40.0g, earthworm extract 100ml (equivalent to crude drug 200.0g) were diluted with water for injection, and the pH was adjusted to 4.5-9.5. Dilute to 2000ml, sterilize and filter, seal in 1000 ampoules of 2ml, and sterilize with high pressure steam to obtain injection; or fill in 1000 vials and freeze-dry to obtain frozen powder injection.

Embodiment 2

[0015] Example 2 Ozagrel 36.5g, sodium hydroxide 6.4g, lumbrokinase 200g, troxerutin 40g, dissolved in water for injection, adjusted to PH4.5-9.5, and fixed to 2000ml, sterile filtered, sealed in 1000 2ml ampoules, sterilized to obtain injection; or poured into 1000 vials to freeze-dry, to obtain freeze-dried powder injection.

Embodiment 3

[0016] Example 3 45.1g of sodium ozagrel, 100ml of extract from leech and earthworm (1:1) (equivalent to 200.0g of crude drug), dissolved in water for injection, adjusted to PH4.5-9.5, and fixed to 2000ml, sterilized Filter, seal in 1000 ampoules of 2ml and sterilize to obtain injection solution or fill in 1000 vials to freeze-dry to obtain freeze-dried powder for injection.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The thrombosis resisting composition consists of thromboxane A2(TXA2) synthetase inhibitor, thrombolytic medicine and / or thrombocyte resisting medicine; and can dissolving thrombus. The composition is obviously superior to single thromboxane A2(TXA2) synthetase inhibitor, and has high effect of preventing and treating thrombus diseases, small dosage and less side effect. Both extracorporeal and intracorporeal experiments shows that the composition has excellent direct thrombus dissolving effect and thrombocyte aggregation inhibiting effect. When the composition of sodium Ozagrel is used in treating acute cerebral thrombus, the clinical total effective rate is 100% and side effect originating rate is 2.1%. While only sodium Ozagrel is used, the corresponding data is 49.2% and 7.6% separately.

Description

Technical field [0001] The invention relates to an antithrombotic composition, which is mainly used for the treatment and prevention of cerebrovascular diseases. Background technique [0002] Cardiovascular and cerebrovascular diseases are diseases that seriously affect human health, and are also one of the diseases with higher morbidity and mortality. Among them, cerebrovascular disease has the highest mortality and disability rate, and its onset age tends to be younger. In view of this, it is urgent to develop efficient and safe drugs for the prevention and treatment of such diseases. [0003] thromboxane A 2 (TXA 2 ) synthetase inhibitors, which have been used to treat acute cerebral thrombosis (such as Ozagrel Sodium, Ozagrel Sodium), but because they can only prevent thrombus formation, they have no direct effect on the formation of thrombus, so the onset is slow (generally Effective after 2 days of medication), the effective rate is low (data show that its effective...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/583A61K35/62A61K35/64A61K35/646A61K38/49A61P7/02
Inventor 田兆军汪慧霞
Owner 田兆军
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com